PASSAGE Trial Shows Tezepelumab Benefit in Diverse Asthma Groups: Njira L. Lugogo, MD, MS

Why It Matters

Demonstrating robust efficacy across historically under‑studied asthma subgroups could expand treatment guidelines and reduce health disparities for patients with severe disease.

Key Takeaways

• Tezepelumab cut overall asthma exacerbations by 70%
• Reductions ranged 54‑77% across all phenotypes
• Benefits confirmed in smokers, COPD, Black, adolescent patients
• Real‑world data supports broader label for severe asthma
• Findings may boost adherence by confirming efficacy in niche groups

Pulse Analysis

Asthma remains a leading chronic disease, affecting roughly 25 million Americans, with severe, uncontrolled cases driving most hospitalizations and costs. Biologic therapies have transformed management, yet pivotal trials often enroll homogenous populations, leaving clinicians uncertain about efficacy in patients who smoke, have comorbid COPD, or belong to racial minorities. Tezepelumab, an anti‑thymic stromal lymphopoietin (TSLP) antibody, showed promise in earlier studies, but real‑world data were needed to confirm its benefit across the full spectrum of disease phenotypes.

The PASSAGE trial (NCT05329194), a phase 4 U.S. study presented at the American Thoracic Society 2026 meeting, enrolled a heterogeneous cohort that mirrored everyday clinical practice. Participants experienced a 70% drop in annualized asthma exacerbation rate overall, while subgroup analyses revealed reductions ranging from 54% to 77% regardless of eosinophil count, smoking status, COPD comorbidity, or Black and adolescent identity. These results validate tezepelumab’s mechanism of action—broad upstream inhibition of airway inflammation—and demonstrate that its efficacy does not depend on traditional biomarkers. By delivering consistent outcomes in groups traditionally excluded from trials, PASSAGE strengthens the evidence base for a more inclusive therapeutic strategy.

For clinicians, the data translate into greater confidence when prescribing tezepelumab to patients who have been historically underserved. Guideline committees may soon incorporate these findings, potentially widening the drug’s label and insurance coverage. Moreover, confirming efficacy in high‑burden populations can improve patient adherence, as individuals see tangible reductions in exacerbations and steroid exposure. The trial also highlights the growing importance of real‑world evidence in shaping respiratory care, encouraging further research that prioritizes health equity while delivering cost‑effective, personalized treatment options.